Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial
- PMID: 25361165
- PMCID: PMC4364250
- DOI: 10.3109/15563650.2014.974263
Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial
Abstract
Background: Crotalidae Polyvalent Immune Fab (Ovine) has been the only antivenom commercially available in the US since 2007 for treatment of Crotalinae envenomation. Late coagulopathy can occur or recur after clearance of Fab antivenom, often after hospital discharge, lasting in some cases more than 2 weeks. There have been serious, even fatal, bleeding complications associated with recurrence phenomena. Frequent follow-up is required, and additional intervention or hospitalization is often necessary. F(ab')2 immunoglobulin derivatives have longer plasma half life than do Fab. We hypothesized that F(ab')2 antivenom would be superior to Fab in the prevention of late coagulopathy following treatment of patients with Crotalinae envenomation.
Methods: We conducted a prospective, double-blind, randomized clinical trial, comparing late coagulopathy in snakebitten patients treated with F(ab')2 with maintenance doses [F(ab')2/F(ab')2], or F(ab')2 with placebo maintenance doses [F(ab')2/placebo], versus Fab with maintenance doses [Fab/Fab]. The primary efficacy endpoint was coagulopathy (platelet count < 150 K/mm(3), fibrinogen level < 150 mg/dL) between end of maintenance dosing and day 8.
Results: 121 patients were randomized at 18 clinical sites and received at least one dose of study drug. 114 completed the study. Of these, 11/37 (29.7%) in the Fab/Fab cohort experienced late coagulopathy versus 4/39 (10.3%, p < 0.05) in the F(ab')2/F(ab')2 cohort and 2/38 (5.3%, p < 0.05) in the F(ab')2/placebo cohort. The lowest heterologous protein exposure was with F(ab')2/placebo. No serious adverse events were related to study drug. In each study arm, one patient experienced an acute serum reaction and one experienced serum sickness.
Conclusions: In this study, management of coagulopathic Crotalinae envenomation with longer-half-life F(ab')2 antivenom, with or without maintenance dosing, reduced the risk of subacute coagulopathy and bleeding following treatment of envenomation.
Keywords: Antivenins; Snakes; Toxinology.
Figures
Comment in
-
The pharmacotherapy for pit viper envenoming in the United States: a brief retrospective on roots, recurrence, and risk.Clin Toxicol (Phila). 2015 Jan;53(1):1-4. doi: 10.3109/15563650.2014.983240. Epub 2014 Nov 28. Clin Toxicol (Phila). 2015. PMID: 25430507 No abstract available.
-
In reply re: "comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial".Clin Toxicol (Phila). 2015 May;53(4):414-5. doi: 10.3109/15563650.2015.1016167. Epub 2015 Feb 23. Clin Toxicol (Phila). 2015. PMID: 25706452 No abstract available.
-
In response to: comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial.Clin Toxicol (Phila). 2015 May;53(4):413. doi: 10.3109/15563650.2015.1016166. Epub 2015 Feb 27. Clin Toxicol (Phila). 2015. PMID: 25723894 No abstract available.
References
-
- Bronstein AC, Spyker DA, Cantilena LR, Jr, Rumack BH, Dart RC. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila) 2012;50:911–1164. - PubMed
-
- Langley RL, Morrow WE. Deaths resulting from animal attacks in the United States. Wilderness Environ Med. 1997;8:8–16. - PubMed
-
- Boyer L, Degan J, Ruha AM, Mallie J, Mangin E, Alagón A. Safety of intravenous equine F(ab')2: insights following clinical trials involving 1534 recipients of scorpion antivenom. Toxicon. 2013;76:386–393. - PubMed
-
- Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med. 2001;37:181–195. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources